definiens: shall mean:1.19.1 CCX282 and all lead compounds and backup compounds targeting CCR9, CCR1 or C5aR and existing as ofthe Effective Date, as listed on Exhibits C, D, or E, as applicable ; or1.19.2 any small molecule compound owned or Controlled by [COMPANY] that has been or is identified orcreated by or on behalf of [COMPANY] as of the Effective Date or during the Research Term, and that meets the followingcriteria:(a ) with respect to Collaboration Targets CCR9, CCR1 and C5aR, such compound interferes with the bindingof endogenous ligands to any one of such Collaboration Targets so as to inhibit the response of any such CollaborationTarget to such endogenous ligands at a therapeutically meaningful level, such level to be established by the JSC during theResearch Term ; and(b ) with respect to Collaboration Target ChemR23, such compound binds to or stimulates such CollaborationTarget at a therapeutically meaningful level, such level to be established by the JSC during the Research Term, therebytriggering a response by ChemR23 positive cells similar to what the receptor ’s interaction with its natural ligand would elicit